Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BR96-doxorubicin immunoconjugate

Known as: cBR96-doxorubicin immunoconjugate, cBR96-DOX, DOX-MOAB BR96 
An antibody-drug conjugate composed of the chimeric monoclonal antibody BR96 chemically linked to the cytotoxic drug doxorubicin. The antibody moiety… Expand
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (2)

BMS 182248SGN-15

Broader (2)

DoxorubicinMonoclonal Antibodies
NCIt Antineoplastic Agent TerminologycBR96-doxorubicin immunoconjugate/gemcitabine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
PURPOSE MLN2704 is an immunoconjugate designed to deliver the maytansinoid antimicrotubule agent drug maytansinoid-1 directly to… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Highly Cited
2007
Highly Cited
2007
Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.
The prodrug bivatuzumab mertansine (BIWI 1) is a novel CD44v6-targeting humanized monoclonal antibody coupled to the toxin… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table II
2004
2004
Stabilization of Chimeric BR96-Doxorubicin Immunoconjugate
Chimeric BR96-doxorubicin conjugate (BR96-DOX) is an immunoconjugate designed to specifically target and kill certain tumor cells… Expand
2001
2001
Selective tumor sensitization to taxanes with the mAb‐drug conjugate cBR96‐doxorubicin
The chimeric monoclonal antibody cBR96 conjugated to doxorubicin (cBR96‐Dox) is selectively internalized by a wide variety of… Expand
Highly Cited
2000
Highly Cited
2000
Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.
OBJECTIVE To evaluate dose intensification with osmotic blood-brain barrier disruption (BBBD) and the potential use of drug… Expand
Highly Cited
1999
Highly Cited
1999
Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.
PURPOSE BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately… Expand
Highly Cited
1997
Highly Cited
1997
Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
The internalizing monoclonal antibody BR96 was conjugated to the anticancer drug doxorubicin (DOX) using an acid-labile hydrazone… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Highly Cited
1996
Highly Cited
1996
A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab*
We have used a combinatorial mutagenesis strategy to humanize BR96, a monoclonal antibody that binds to the Lewis Y class of… Expand
1995
1995
Analysis of monoclonal antibody chimeric BR96-doxorubicin immunoconjugate by sodium dodecyl sulfate-capillary gel electrophoresis with ultraviolet and laser-induced fluorescence detection.
Sodium dodecyl sulfate-capillary gel electrophoresis (SDS-CAGE), the capillary version of SDS-polyacrylamide-based slab gel… Expand
Highly Cited
1993
Highly Cited
1993
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE